COHANCE
Cohance Lifesciences Limited engages in the contract research, development, and manufacturing of new chemical entity (NCE) based intermediates, active pharmaceutical ingredients (API), specialty chemicals, and formulated drugs in India, the United States, Europe, and internationally. The company offers small molecule APIs, advanced intermediates, and starting materials; antibody drug conjugates; … Read more
COHANCE (COHANCE) - Total Assets
Latest total assets as of September 2025: ₹55.68 Billion INR
Based on the latest financial reports, COHANCE (COHANCE) holds total assets worth ₹55.68 Billion INR as of September 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
COHANCE - Total Assets Trend (2019–2025)
This chart illustrates how COHANCE’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
COHANCE - Asset Composition Analysis
Current Asset Composition (March 2025)
COHANCE's total assets of ₹55.68 Billion consist of 29.3% current assets and 70.7% non-current assets.
| Asset Category | Amount (INR) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ₹0.00 | 2.8% |
| Accounts Receivable | ₹2.85 Billion | 9.4% |
| Inventory | ₹1.67 Billion | 5.5% |
| Property, Plant & Equipment | ₹0.00 | 0.0% |
| Intangible Assets | ₹638.90 Million | 2.1% |
| Goodwill | ₹6.55 Billion | 21.6% |
Asset Composition Trend (2019–2025)
This chart illustrates how COHANCE's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: COHANCE's current assets represent 29.3% of total assets in 2025, a decrease from 49.8% in 2019.
- Cash Position: Cash and equivalents constituted 2.8% of total assets in 2025, up from 1.4% in 2019.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 23.0% of total assets, an increase from 0.0% in 2019.
- Asset Diversification: The largest asset category is goodwill at 21.6% of total assets.
COHANCE Competitors by Total Assets
Key competitors of COHANCE based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Swedish Orphan Biovitrum AB (publ)
PINK:BIOVF
|
USA | $67.26 Billion |
|
Kamada
NASDAQ:KMDA
|
USA | $378.79 Million |
|
One World Pharma Inc
OTCQB:OWPC
|
USA | $6.62 Million |
|
Dongwha Pharm.Co.Ltd
KO:000020
|
Korea | ₩654.63 Billion |
|
Shenzhen Neptunus Bioengineering Co Ltd
SHE:000078
|
China | CN¥27.28 Billion |
|
Yuhan Corp.
KO:000100
|
Korea | ₩3.05 Trillion |
|
Anhui Fengyuan Pharmaceutical Co Ltd
SHE:000153
|
China | CN¥4.97 Billion |
|
Kotra Industries Bhd
KLSE:0002
|
Malaysia | RM363.90 Million |
COHANCE - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - COHANCE generates 0.40x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Solid ROA - For every $100 in assets, COHANCE generates $8.84 in net profit.
COHANCE - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 2.92 | 4.90 | 2.21 |
| Quick Ratio | 1.98 | 4.00 | 1.30 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | ₹12.14 Billion | ₹ 9.30 Billion | ₹ 2.63 Billion |
COHANCE - Advanced Valuation Insights
This section examines the relationship between COHANCE's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 23.62 |
| Latest Market Cap to Assets Ratio | 0.02 |
| Asset Growth Rate (YoY) | 34.5% |
| Total Assets | ₹30.32 Billion |
| Market Capitalization | $531.19 Million USD |
Valuation Analysis
Below Book Valuation: The market values COHANCE's assets below their book value (0.02 x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: COHANCE's assets grew by 34.5% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for COHANCE (2019–2025)
The table below shows the annual total assets of COHANCE from 2019 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-03-31 | ₹30.32 Billion | +34.50% |
| 2024-03-31 | ₹22.54 Billion | +14.67% |
| 2023-03-31 | ₹19.66 Billion | +7.44% |
| 2022-03-31 | ₹18.30 Billion | +24.08% |
| 2021-03-31 | ₹14.74 Billion | +25.72% |
| 2020-03-31 | ₹11.73 Billion | +49.78% |
| 2019-03-31 | ₹7.83 Billion | -- |